Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors.
Identifieur interne : 000A43 ( Main/Exploration ); précédent : 000A42; suivant : 000A44Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors.
Auteurs : Guy Boivin [Canada] ; Nathalie GoyetteSource :
- Antiviral research [ 0166-3542 ] ; 2002.
Descripteurs français
- KwdFr :
- Acides sialiques (pharmacologie), Acétamides (pharmacologie), Antienzymes (pharmacologie), Canada (MeSH), Concentration inhibitrice 50 (MeSH), Cyclopentanes (pharmacologie), Fluorimétrie (MeSH), Grippe humaine (traitement médicamenteux), Guanidines (MeSH), Humains (MeSH), Mesures de luminescence (MeSH), Oséltamivir (MeSH), Pyrannes (MeSH), Résistance virale aux médicaments (MeSH), Sialidase (antagonistes et inhibiteurs), Virus de la grippe A (effets des médicaments et des substances chimiques), Virus de la grippe A (enzymologie), Virus influenza B (effets des médicaments et des substances chimiques), Virus influenza B (enzymologie), Zanamivir (MeSH).
- MESH :
- antagonistes et inhibiteurs : Sialidase.
- effets des médicaments et des substances chimiques : Virus de la grippe A, Virus influenza B.
- enzymologie : Virus de la grippe A, Virus influenza B.
- pharmacologie : Acides sialiques, Acétamides, Antienzymes, Cyclopentanes.
- traitement médicamenteux : Grippe humaine.
- Canada, Concentration inhibitrice 50, Fluorimétrie, Guanidines, Humains, Mesures de luminescence, Oséltamivir, Pyrannes, Résistance virale aux médicaments, Zanamivir.
- Wicri :
- geographic : Canada.
English descriptors
- KwdEn :
- Acetamides (pharmacology), Canada (MeSH), Cyclopentanes (pharmacology), Drug Resistance, Viral (MeSH), Enzyme Inhibitors (pharmacology), Fluorometry (MeSH), Guanidines (MeSH), Humans (MeSH), Influenza A virus (drug effects), Influenza A virus (enzymology), Influenza B virus (drug effects), Influenza B virus (enzymology), Influenza, Human (drug therapy), Inhibitory Concentration 50 (MeSH), Luminescent Measurements (MeSH), Neuraminidase (antagonists & inhibitors), Oseltamivir (MeSH), Pyrans (MeSH), Sialic Acids (pharmacology), Zanamivir (MeSH).
- MESH :
- chemical , antagonists & inhibitors : Neuraminidase.
- chemical , pharmacology : Acetamides, Cyclopentanes, Enzyme Inhibitors, Sialic Acids.
- geographic : Canada, Guanidines, Oseltamivir, Pyrans, Zanamivir.
- drug effects : Influenza A virus, Influenza B virus.
- drug therapy : Influenza, Human.
- enzymology : Influenza A virus, Influenza B virus.
- Drug Resistance, Viral, Fluorometry, Humans, Inhibitory Concentration 50, Luminescent Measurements.
Abstract
Forty-two influenza A and 23 influenza B isolates collected from untreated subjects during the 1999-2000 influenza season in Canada were tested for their susceptibility to three neuraminidase inhibitors (zanamivir, oseltamivir carboxylate and RWJ-270201 or BCX-1812) using a chemiluminescent neuraminidase assay. Influenza B isolates were less susceptible than A viruses to all tested drugs. RWJ-270201 was the most potent drug against both influenza A(H3N2) (mean IC(50): 0.60 nM) and B (mean IC(50): 0.87 nM) viruses. Oseltamivir carboxylate was more active than zanamivir for influenza A(H3N2) isolates (mean IC(50): 0.73 vs. 2.09 nM) whereas it was less potent against B viruses (mean IC(50): 11.53 vs. 4.15 nM).
DOI: 10.1016/s0166-3542(01)00219-4
PubMed: 12062387
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors.</title><author><name sortKey="Boivin, Guy" sort="Boivin, Guy" uniqKey="Boivin G" first="Guy" last="Boivin">Guy Boivin</name><affiliation wicri:level="1"><nlm:affiliation>Research Center in Infectious Diseases, CHUQ-CHUL, Room RC-709, 2705 Blvd. Laurier, Sainte-Foy, Québec, Canada G1V4G2. guy.boivin@crchul.ulaval.ca</nlm:affiliation><country>Canada</country><wicri:regionArea>Research Center in Infectious Diseases, CHUQ-CHUL, Room RC-709, 2705 Blvd. Laurier, Sainte-Foy, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Goyette, Nathalie" sort="Goyette, Nathalie" uniqKey="Goyette N" first="Nathalie" last="Goyette">Nathalie Goyette</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2002">2002</date><idno type="RBID">pubmed:12062387</idno><idno type="pmid">12062387</idno><idno type="doi">10.1016/s0166-3542(01)00219-4</idno><idno type="wicri:Area/Main/Corpus">000A57</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000A57</idno><idno type="wicri:Area/Main/Curation">000A57</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000A57</idno><idno type="wicri:Area/Main/Exploration">000A57</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors.</title><author><name sortKey="Boivin, Guy" sort="Boivin, Guy" uniqKey="Boivin G" first="Guy" last="Boivin">Guy Boivin</name><affiliation wicri:level="1"><nlm:affiliation>Research Center in Infectious Diseases, CHUQ-CHUL, Room RC-709, 2705 Blvd. Laurier, Sainte-Foy, Québec, Canada G1V4G2. guy.boivin@crchul.ulaval.ca</nlm:affiliation><country>Canada</country><wicri:regionArea>Research Center in Infectious Diseases, CHUQ-CHUL, Room RC-709, 2705 Blvd. Laurier, Sainte-Foy, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Goyette, Nathalie" sort="Goyette, Nathalie" uniqKey="Goyette N" first="Nathalie" last="Goyette">Nathalie Goyette</name></author></analytic><series><title level="j">Antiviral research</title><idno type="ISSN">0166-3542</idno><imprint><date when="2002" type="published">2002</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acetamides (pharmacology)</term><term>Canada (MeSH)</term><term>Cyclopentanes (pharmacology)</term><term>Drug Resistance, Viral (MeSH)</term><term>Enzyme Inhibitors (pharmacology)</term><term>Fluorometry (MeSH)</term><term>Guanidines (MeSH)</term><term>Humans (MeSH)</term><term>Influenza A virus (drug effects)</term><term>Influenza A virus (enzymology)</term><term>Influenza B virus (drug effects)</term><term>Influenza B virus (enzymology)</term><term>Influenza, Human (drug therapy)</term><term>Inhibitory Concentration 50 (MeSH)</term><term>Luminescent Measurements (MeSH)</term><term>Neuraminidase (antagonists & inhibitors)</term><term>Oseltamivir (MeSH)</term><term>Pyrans (MeSH)</term><term>Sialic Acids (pharmacology)</term><term>Zanamivir (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Acides sialiques (pharmacologie)</term><term>Acétamides (pharmacologie)</term><term>Antienzymes (pharmacologie)</term><term>Canada (MeSH)</term><term>Concentration inhibitrice 50 (MeSH)</term><term>Cyclopentanes (pharmacologie)</term><term>Fluorimétrie (MeSH)</term><term>Grippe humaine (traitement médicamenteux)</term><term>Guanidines (MeSH)</term><term>Humains (MeSH)</term><term>Mesures de luminescence (MeSH)</term><term>Oséltamivir (MeSH)</term><term>Pyrannes (MeSH)</term><term>Résistance virale aux médicaments (MeSH)</term><term>Sialidase (antagonistes et inhibiteurs)</term><term>Virus de la grippe A (effets des médicaments et des substances chimiques)</term><term>Virus de la grippe A (enzymologie)</term><term>Virus influenza B (effets des médicaments et des substances chimiques)</term><term>Virus influenza B (enzymologie)</term><term>Zanamivir (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Neuraminidase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Acetamides</term><term>Cyclopentanes</term><term>Enzyme Inhibitors</term><term>Sialic Acids</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Canada</term><term>Guanidines</term><term>Oseltamivir</term><term>Pyrans</term><term>Zanamivir</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Sialidase</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Influenza A virus</term><term>Influenza B virus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Virus de la grippe A</term><term>Virus influenza B</term></keywords><keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>Virus de la grippe A</term><term>Virus influenza B</term></keywords><keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>Influenza A virus</term><term>Influenza B virus</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Acides sialiques</term><term>Acétamides</term><term>Antienzymes</term><term>Cyclopentanes</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Resistance, Viral</term><term>Fluorometry</term><term>Humans</term><term>Inhibitory Concentration 50</term><term>Luminescent Measurements</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Canada</term><term>Concentration inhibitrice 50</term><term>Fluorimétrie</term><term>Guanidines</term><term>Humains</term><term>Mesures de luminescence</term><term>Oséltamivir</term><term>Pyrannes</term><term>Résistance virale aux médicaments</term><term>Zanamivir</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Canada</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Forty-two influenza A and 23 influenza B isolates collected from untreated subjects during the 1999-2000 influenza season in Canada were tested for their susceptibility to three neuraminidase inhibitors (zanamivir, oseltamivir carboxylate and RWJ-270201 or BCX-1812) using a chemiluminescent neuraminidase assay. Influenza B isolates were less susceptible than A viruses to all tested drugs. RWJ-270201 was the most potent drug against both influenza A(H3N2) (mean IC(50): 0.60 nM) and B (mean IC(50): 0.87 nM) viruses. Oseltamivir carboxylate was more active than zanamivir for influenza A(H3N2) isolates (mean IC(50): 0.73 vs. 2.09 nM) whereas it was less potent against B viruses (mean IC(50): 11.53 vs. 4.15 nM).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12062387</PMID><DateCompleted><Year>2002</Year><Month>07</Month><Day>18</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0166-3542</ISSN><JournalIssue CitedMedium="Print"><Volume>54</Volume><Issue>3</Issue><PubDate><Year>2002</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Antiviral research</Title><ISOAbbreviation>Antiviral Res.</ISOAbbreviation></Journal><ArticleTitle>Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors.</ArticleTitle><Pagination><MedlinePgn>143-7</MedlinePgn></Pagination><Abstract><AbstractText>Forty-two influenza A and 23 influenza B isolates collected from untreated subjects during the 1999-2000 influenza season in Canada were tested for their susceptibility to three neuraminidase inhibitors (zanamivir, oseltamivir carboxylate and RWJ-270201 or BCX-1812) using a chemiluminescent neuraminidase assay. Influenza B isolates were less susceptible than A viruses to all tested drugs. RWJ-270201 was the most potent drug against both influenza A(H3N2) (mean IC(50): 0.60 nM) and B (mean IC(50): 0.87 nM) viruses. Oseltamivir carboxylate was more active than zanamivir for influenza A(H3N2) isolates (mean IC(50): 0.73 vs. 2.09 nM) whereas it was less potent against B viruses (mean IC(50): 11.53 vs. 4.15 nM).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boivin</LastName><ForeName>Guy</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Research Center in Infectious Diseases, CHUQ-CHUL, Room RC-709, 2705 Blvd. Laurier, Sainte-Foy, Québec, Canada G1V4G2. guy.boivin@crchul.ulaval.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goyette</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Antiviral Res</MedlineTA><NlmUniqueID>8109699</NlmUniqueID><ISSNLinking>0166-3542</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000081">Acetamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003517">Cyclopentanes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006146">Guanidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011714">Pyrans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012794">Sialic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>20O93L6F9H</RegistryNumber><NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber><NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6O3XI777I</RegistryNumber><NameOfSubstance UI="D053243">Zanamivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>QW7Y7ZR15U</RegistryNumber><NameOfSubstance UI="C414210">peramivir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000081" MajorTopicYN="N">Acetamides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003517" MajorTopicYN="N">Cyclopentanes</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005470" MajorTopicYN="N">Fluorometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006146" MajorTopicYN="N">Guanidines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009981" MajorTopicYN="N">Influenza B virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020128" MajorTopicYN="N">Inhibitory Concentration 50</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008163" MajorTopicYN="N">Luminescent Measurements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053139" MajorTopicYN="N">Oseltamivir</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011714" MajorTopicYN="N">Pyrans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012794" MajorTopicYN="N">Sialic Acids</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053243" MajorTopicYN="N">Zanamivir</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>6</Month><Day>14</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>7</Month><Day>19</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>6</Month><Day>14</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12062387</ArticleId><ArticleId IdType="pii">S0166354201002194</ArticleId><ArticleId IdType="doi">10.1016/s0166-3542(01)00219-4</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Goyette, Nathalie" sort="Goyette, Nathalie" uniqKey="Goyette N" first="Nathalie" last="Goyette">Nathalie Goyette</name></noCountry><country name="Canada"><noRegion><name sortKey="Boivin, Guy" sort="Boivin, Guy" uniqKey="Boivin G" first="Guy" last="Boivin">Guy Boivin</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeCanadaV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A43 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A43 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeCanadaV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:12062387
|texte= Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:12062387" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeCanadaV4
| This area was generated with Dilib version V0.6.35. |  |